Wegovy FlexTouch Pen: Four-Dose Pen Guide

Learn how the Wegovy FlexTouch four-dose pen differs from single-dose Wegovy pens, including fixed dosing, needles, storage, safety, and disposal.

WEIGHT MANAGEMENT

Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare

9/7/20268 min read

Wegovy FlexTouch Pen: What Patients Should Know About the Four-Dose Pen

Wegovy® has traditionally been supplied in the United States as single-dose autoinjectors. The Wegovy® FlexTouch® pen provides another device option: one prefilled pen containing four weekly doses of semaglutide.

The medication is still Wegovy, but the multi-dose FlexTouch device works differently from the familiar single-use autoinjector. It requires a separate disposable needle, remains in use for several weeks, and has different storage and disposal considerations.

This article explains the major differences between the devices. It does not replace the prescription label, manufacturer’s Instructions for Use, or hands-on device training.

Readers seeking a broader overview of available products can also review Wegovy Pens for Weight Loss: Doses, Devices, Benefits, and Risks (publish 10/01/2026)

What Is the Wegovy FlexTouch Pen?

The U.S. Wegovy FlexTouch pen is a prefilled, multi-dose pen intended for use by one person. The current device contains:

Four fixed doses of Wegovy 2.4 mg
A dose selector and dose counter
Four disposable NovoFine® Plus needles
One weekly dose for four weeks

Unlike a single-dose autoinjector, the FlexTouch pen is retained after each of the first three injections. A new needle is attached for each dose and removed afterward.

The FlexTouch pen does not contain multiple selectable Wegovy strengths. The current U.S. product delivers a fixed 2.4 mg dose.

How Is FlexTouch Different From the Single-Dose Wegovy Pen?

The original Wegovy pen is a disposable autoinjector. Its needle is built into the device and remains hidden. Each pen contains one preset dose and is discarded after use.

The FlexTouch device:

Contains four doses in one pen
Uses a new external needle for each dose
Requires a flow check before the first dose from a new pen
Uses a dose selector and visible dose counter
Must be stored between weekly doses
Is discarded after all four doses have been used

These differences affect device handling, storage, needle disposal, and troubleshooting. Familiarity with an Ozempic® or insulin pen does not replace the product-specific Wegovy instructions.

Does FlexTouch Allow Smaller or Customized Doses?

No. The U.S. Wegovy FlexTouch pen contains four fixed 2.4 mg doses. It is not designed to deliver starter doses, partial doses, customized doses, or “microdoses.”

The manufacturer instructs users to confirm the displayed dose rather than estimating a dose by counting clicks. Click counting is not an approved dosing method.

If the counter cannot reach the full labeled dose, the pen does not contain enough medication for another complete injection. Residual medication is not intended to be withdrawn with a syringe or combined with medication from another pen.

The standard Wegovy escalation schedule begins below 2.4 mg. Therefore, this FlexTouch presentation is not a replacement for the lower-dose products used earlier in treatment. More information is available in Increasing Your GLP-1 Dose: Why Side Effects Can Return and Why Faster Isn’t Always Better.

Why Device Training Matters

The FlexTouch pen has more user-operated steps than the single-dose autoinjector. Important concepts include:

Confirming the correct product and strength
Inspecting the pen and medication
Attaching a new compatible needle
Performing the required first-use flow check
Using the dose selector and counter
Keeping the needle in place for the full delivery time
Removing and discarding the needle after each injection
Storing the pen correctly between doses

The complete sequence is illustrated in the official Wegovy Prescribing Information and FlexTouch Instructions for Use. That document—not a blog post or social-media demonstration—is the authoritative source for operating the device.

What Is the Flow Check?

The Instructions for Use describe a medication-flow check before the first injection from each new FlexTouch pen. Its purpose is to confirm that medication can move through the pen and needle.

The flow check is associated with starting a new pen, not with routine dosing before every injection from the same pen. A missing drop during the check can reflect a needle or device problem and should be handled according to the manufacturer’s troubleshooting directions.

An uncertain device function should not be corrected by guessing how much medication was delivered or automatically administering another full dose.

What Does the Dose Counter Show?

The dose counter is the visual confirmation of the selected and delivered dose. For the current U.S. FlexTouch pen, the labeled dose is 2.4 mg.

During delivery, the counter returns toward zero. The manufacturer also specifies a brief waiting period with the needle still under the skin after the counter reaches zero so the complete dose can be delivered.

The displayed number—not the sound or number of clicks—is the relevant device indicator.

Where Is Wegovy Injected?

Wegovy is administered subcutaneously, meaning into the fatty tissue beneath the skin rather than into a muscle or vein.

The prescribing information lists the abdomen, thigh, and upper arm as injection areas. Product instructions also address rotating the specific injection location and avoiding irritated, bruised, scarred, hard, or tender skin.

This article intentionally does not provide individualized site selection or injection technique. Those details belong in the manufacturer’s Instructions for Use and device training.

Why Must a New Needle Be Used Each Time?

The FlexTouch pen is reusable for four doses, but the needle is not.

Needle reuse can contribute to:

Contamination or infection
Needle blockage
Medication leakage
Damage or dulling
Inaccurate delivery

The needle is removed after each dose, and the pen is stored without a needle attached. Leaving a needle connected can introduce air or contamination, permit leakage, or affect the next dose.

Used needles and completed pens belong in an appropriate sharps container. The FDA provides detailed safe sharps-disposal guidance, and local disposal rules may also apply.

Can the Wegovy FlexTouch Pen Be Shared?

No. The pen is intended for one person only, even when the needle is changed.

Blood or other biological material can enter a reusable injection device during use. Sharing can therefore transmit serious infection. Needles must also never be shared.

How Is the FlexTouch Pen Stored?

The current Instructions for Use provide different storage rules before and after the first dose.

Before first use, the FlexTouch pen is refrigerated at 36°F to 46°F. After first use, it may be kept refrigerated or at controlled room temperature between 68°F and 77°F for up to 56 days.

The pen should remain capped, protected from excessive heat and light, and stored without a needle attached. Frozen medication or medication exposed to temperatures above the labeled limit should not be used.

Storage rules vary among GLP-1 products and device presentations. The original single-dose Wegovy pens and the multi-dose FlexTouch pen should not be assumed to have identical instructions. See How to Store GLP-1 Medications Safely (coming 01/21/2027) for a broader storage overview.

What Happens After the Fourth Dose?

A small amount of liquid may remain visible after four complete doses. This residual volume is not an additional dose.

The manufacturer directs users to dispose of the pen after all four labeled doses have been delivered. Residual medication should not be extracted with a syringe or combined with another pen.

FDA-cleared sharps containers are designed to reduce accidental needle sticks and exposure to used injection devices. Community disposal requirements determine how a filled container is ultimately discarded.

What If the Pen Is Dropped or Does Not Work as Expected?

Possible device concerns include:

No medication appearing during the first-use flow check
A dose counter that cannot reach 2.4 mg
A counter that does not return to zero
A bent, blocked, or damaged needle
Medication streaming rather than forming a small drop
A pen that has been dropped or appears damaged

An uncertain injection should not be treated as proof that no medication was delivered. Immediately repeating a full dose could result in excessive exposure if the first injection was partially or fully delivered.

The pen and packaging may be useful when the pharmacy, prescriber, or manufacturer reviews a device complaint. Novo Nordisk’s current contact information appears in the official prescribing materials.

Does FlexTouch Change Wegovy’s Side Effects?

No. FlexTouch changes the delivery device, not the active ingredient. It still contains semaglutide and carries the same medication-related warnings and adverse effects as injectable Wegovy.

Commonly reported effects include:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal discomfort
Indigestion or reflux
Bloating
Fatigue
Headache
Dizziness
Belching or gas

These effects are reviewed in more detail in Most Common GLP-1 Side Effects: Why They Happen and What You Can Do.

Device technique can influence whether a complete dose is delivered, but it does not eliminate semaglutide’s pharmacologic effects or safety risks.

Which Symptoms Require Medical Evaluation?

Severe or persistent symptoms are not ordinary device issues. Examples include:

Repeated vomiting or inability to maintain fluids
Signs of significant dehydration
Severe or persistent abdominal pain
Right-upper abdominal pain with fever or jaundice
Significant vision changes
Severe constipation with pain, vomiting, or abdominal swelling
Symptoms of a serious allergic reaction

Severe abdominal symptoms can have several causes. OVH provides separate educational articles about nausea on GLP-1 medications and gallstones and GLP-1 medications (coming 12/28/2026)

Emergency symptoms—including difficulty breathing, swelling of the face or throat, fainting, or other signs of a severe allergic reaction—require emergency care.

Important Wegovy Safety Information

Wegovy is not appropriate for everyone. Its prescribing information includes a boxed warning concerning thyroid C-cell tumors observed in rodents. The medication is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Additional warnings address pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, serious gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and hypoglycemia when combined with certain glucose-lowering medications.

The label also recommends discontinuing Wegovy at least two months before a planned pregnancy because semaglutide remains in the body for an extended period.

For a focused explanation of the boxed warning, see Thyroid C-Cell Tumor Warning and GLP-1 Medications coming 10/12/2026.

The Most Important FlexTouch Facts

The Wegovy FlexTouch pen:

Contains four fixed 2.4 mg doses
Uses a new disposable needle for each dose
Requires a flow check before the first dose from each new pen
Uses a dose counter rather than click counting
Must be stored between doses
Is intended for one person only
Is discarded after the fourth labeled dose

It is not a starter pen, an adjustable-dose device, or a way to create partial doses.

The safest source for operating instructions is the current manufacturer-provided Instructions for Use. A blog can explain how the device differs, but it should not replace product-specific training.

Ready to Learn More About Medical Weight Management?

At Optima Vida Healthcare, weight-management evaluations consider health history, previous treatments, medication response, side effects, goals, and long-term needs. Treatment may include lifestyle support, laboratory evaluation, and medication when clinically appropriate.

Oklahoma patients can learn more about telehealth weight-loss treatment, eligibility, and follow-up.

Start Your Weight-Management Evaluation →

Visit www.ovhmed.com for more information.

The visit fee covers medical evaluation and related clinical services only. Medication, pharmacy, laboratory, and other third-party costs are separate unless specifically stated. A prescription is not guaranteed. Prescribing decisions are made by a licensed healthcare provider after clinical evaluation.

Medical Disclaimer

This article is for general educational purposes only. It does not provide individualized medical advice, injection training, diagnosis, or treatment instructions and does not establish a provider-patient relationship. The prescription label and manufacturer’s Instructions for Use control the operation, storage, and disposal of a specific medication device.

References

Novo Nordisk. Wegovy prescribing information and FlexTouch Instructions for Use. 2026. Official prescribing information
U.S. Food and Drug Administration. Wegovy approval labeling: Multi-dose FlexTouch pen. 2026. FDA-approved label
U.S. Food and Drug Administration. Safely using sharps at home, at work, and while traveling. FDA sharps guidance
U.S. Food and Drug Administration. Sharps disposal containers. FDA disposal guidance

SEO title: Wegovy FlexTouch Pen: Four-Dose Pen Guide
Meta description: Learn how the Wegovy FlexTouch four-dose pen differs from single-dose Wegovy pens, including fixed dosing, needles, storage, safety, and disposal.
Suggested URL slug: /wegovy-flextouch-four-dose-pen
Primary keyword: Wegovy FlexTouch pen
Secondary keywords: Wegovy four-dose pen, Wegovy multi-dose pen, Wegovy FlexTouch 2.4 mg, Wegovy pen storage, Wegovy FlexTouch instructions, Wegovy pen needles
Excerpt: The Wegovy FlexTouch pen contains four fixed 2.4 mg doses and works differently from the single-dose autoinjector. Learn about its design, storage, needles, safety, and disposal.